RYBREVANT® is the first and only antibody treatment designed to target mNSCLC with EGFR exon 20 insertion mutations
40% of people treated with RYBREVANT® after chemotherapy that contains platinum saw their tumors disappear (3.7%) or get smaller (36%).
EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer.
Register for Updates
Sign up to receive the latest news and information about RYBREVANT®